Public T cell receptors confer high-avidity CD4 responses to HIV controllers

Journal of Clinical Investigation

Volumn 126, Issue 6, 2016, Pages 2093-2108

  Benati, Daniela ^a   Galperin, Moran ^a   Lambotte, Olivier ^b,c,d,e   Gras, Stéphanie ^f   Lim, Annick ^a   Mukhopadhyay, Madhura ^a   Nouël, Alexandre ^a   Campbell, Kristy Anne ^f   Lemercier, Brigitte ^a   Claireaux, Mathieu ^a   Hendou, Samia ^g   Lechat, Pierre ^a   De Truchis, Pierre ^h   Boufassa, Faroudy ^g   Rossjohn, Jamie ^f,i   Delfraissy, Jean François ^b,c,d   Arenzana Seisdedos, Fernando ^a,j   Chakrabarti, Lisa A ^a,j  

^a INSTITUT PASTEUR   (France)

^b INSERM U1184   (France)

^c BICÊTRE HOSPITAL   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e DIF   (France)

^f MONASH UNIVERSITY   (Australia)

^g CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^h RAYMOND POINCARÉ HOSPITAL   (France)

ⁱ CARDIFF UNIVERSITY   (United Kingdom)

^j INSERM   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; GAG293 PEPTIDE; HLA DR ANTIGEN; HLA DRB1 ANTIGEN; HLA DRB5 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; UNCLASSIFIED DRUG; GAG PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE FREQUENCY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFECTION CONTROL; MIDDLE AGED; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE RECEPTOR ALPHA VARIABLE GENE; T LYMPHOCYTE RECEPTOR BETA C VARIABLE GENE; TRBD GENE; TRBJ GENE; VIRUS CAPSID; VIRUS GENE; ADOPTIVE TRANSFER; ANIMAL; CELLULAR IMMUNITY; GENETICS; HIV INFECTIONS; HIV SURVIVOR; IMMUNOLOGY; L CELL LINE; MOUSE; T LYMPHOCYTE RECEPTOR GENE;

ADOPTIVE TRANSFER; ADULT; ANIMALS; ANTIGENS, CD4; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENES, T-CELL RECEPTOR ALPHA; GENES, T-CELL RECEPTOR BETA; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HIV-1; HLA-DR ANTIGENS; HUMANS; IMMUNITY, CELLULAR; L CELLS (CELL LINE); MICE; MIDDLE AGED; RECEPTORS, ANTIGEN, T-CELL;

EID: 84974627200     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI83792     Document Type: Article

References (54)

1. Deeks SG, et al. Systemic effects of inflammation on health during chronic HIV infection. Immunity. 2013;39(4):633-645.
2. + T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med. 1997;3(5):533-540.
3. + repertoire during antiviral therapy. Nat Med. 1998;4(2):215-221.
4. + T cell responses associated with control of viremia. Science. 1997;278(5342):1447-1450.
5. + T cells. Nature. 2002;417(6884):95-98.
6. Lubong Sabado R, et al. In vitro priming recapitulates in vivo HIV-1 specific T cell responses, revealing rapid loss of virus reactive CD4 T cells in acute HIV-1 infection. PLoS One. 2009;4(1):e4256.
7. Lambotte O, et al. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis. 2005;41(7):1053-1056.
8. Chakrabarti LA, Simon V. Immune mechanisms of HIV control. Curr Opin Immunol. 2010;22(4):488-496.
9. Saez-Cirion A, et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar CTL activation phenotype. Proc Natl Acad Sci U S A. 2007;104(16):6776-6781.
10. + T-cell polyfunctionality and HIV-suppressive activity. Blood. 2009;113(25):6351-6360.
11. + T cells. Immunity. 2013;38(3):425-436.
12. Chen H, et al. TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection. Nat Immunol. 2012;13(7):691-700.
13. + T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med. 2007;204(10):2473-2485.
14. Iglesias MC, et al. Escape from highly effective public CD8+ T-cell clonotypes by HIV. Blood. 2011;118(8):2138-2149.
15. + T cells endowed with proliferative capacity. J Exp Med. 2003;198(12):1909-1922.
16. Harari A, et al. Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol. 2005;174(2):1037-1045.
17. van Grevenynghe J, et al. Transcription factor FOXO3a controls the persistence of memory CD4(+) T cells during HIV infection. Nat Med. 2008;14(3):266-274.
18. + T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J Virol. 2007;81(24):13904-13915.
19. Kaufmann DE, et al. Limited durability of viral control following treated acute HIV infection. PLoS Med. 2004;1(2):e36.
20. Ranasinghe S, et al. HIV-specific CD4 T cell responses to different viral proteins have discordant associations with viral load and clinical outcome. J Virol. 2012;86(1):277-283.
21. + T-cell responses. J Virol. 2010;84(21):11020-11029.
22. Vingert B, et al. HIV controllers maintain a population of highly efficient Th1 effector cells in contrast to patients treated in the long term. J Virol. 2012;86(19):10661-10674.
23. + T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol. 2007;8(11):1246-1254.
24. Porichis F, et al. Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood. 2011;118(4):965-974.
25. + T cells respond to minimal amounts of Gag antigen due to high TCR avidity. PLoS Pathog. 2010;6(2):e1000780.
26. + T cells: optimal soldiers in the war against viruses and tumors. Immunol Res. 2005;31(1):13-24.
27. Berger CT, et al. High functional avidity CTL responses to HLA-B-restricted Gag-derived epitopes associate with relative HIV control. J Virol. 2011;85(18):9334-9345.
28. Kaufmann DE, et al. Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. J Virol. 2004;78(9):4463-4477.
29. Wooldridge L, et al. Tricks with tetramers: how to get the most from multimeric peptide-MHC. Immunology. 2009;126(2):147-164.
30. Lim A, et al. Frequent contribution of T cell clonotypes with public TCR features to the chronic response against a dominant EBV-derived epitope: application to direct detection of their molecular imprint on the human peripheral T cell repertoire. J Immunol. 2000;165(4):2001-2011.
31. Hacein-Bey-Abina S, et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2010;363(4):355-364.
32. Alamyar E, et al. IMGT((R)) tools for the nucleotide analysis of immunoglobulin (IG) and T cell receptor (TR) V-(D)-J repertoires, polymorphisms, and IG mutations: IMGT/V-QUEST and IMGT/HighV-QUEST for NGS. Methods Mol Biol. 2012;882:569-604.
33. Venturi V, et al. A mechanism for TCR sharing between T cell subsets and individuals revealed by pyrosequencing. J Immunol. 2011;186(7):4285-4294.
34. Turner SJ, et al. Structural determinants of T-cell receptor bias in immunity. Nat Rev Immunol. 2006;6(12):883-894.
35. Gras S, et al. T-cell receptor bias and immunity. Curr Opin Immunol. 2008;20(1):119-125.
36. Rossjohn J, et al. T cell antigen receptor recognition of antigen-presenting molecules. Annu Rev Immunol. 2015;33:169-200.
37. + T cells. Blood. 2006;107(12):4781-4789.
38. Liu P, et al. Characterization of human alphabeta-TCR repertoire and discovery of D-D fusion in TCRbeta chains. Protein Cell. 2014;5(8):603-615.
39. Gillespie GM, et al. Strong TCR conservation and altered T cell cross-reactivity characterize a B∗57-restricted immune response in HIV-1 infection. J Immunol. 2006;177(6):3893-3902.
40. + TCR bias immunodominance in HIV-1 infection. J Immunol. 2015;194(11):5329-5345.
41. + T cell repertoire in the transition from effector to memory. Immunity. 2008;28(4):533-545.
42. + CTLs in delay of AIDS viral dissemination from mucosa. Blood. 2006;107(8):3258-3264.
43. Corse E, et al. Attenuated T cell responses to a high-potency ligand in vivo. PLoS Biol. 2010;8(9):e1000481 .
44. Valitutti S. The serial engagement model 17 years after: from TCR triggering to immunotherapy. Front Immunol. 2012;3:272.
45. + T cell response to a vectored retroviral antigen is determined by its speed. J Immunol. 2014;193(4):1567-1577.
46. Swain SL, et al. Expanding roles for CD4(+) T cells in immunity to viruses. Nat Rev Immunol. 2012;12(2):136-148.
47. Blanco-Melo D, et al. Intrinsic cellular defenses against human immunodeficiency viruses. Immunity. 2012;37(3):399-411.
48. + T helper lymphocyte subtypes modulate HIV-1 infectivity. PLoS Pathog. 2009;5(2):e1000292.
49. Oswald-Richter K, et al. Identification of a CCR5-expressing T cell subset that is resistant to R5-tropic HIV infection. PLoS Pathog. 2007;3(4):e58.
50. + T cells from HIV controllers. Blood. 2011;118(4):955-964.
51. Reinherz EL, Wang JH. Codification of bidentate pMHC interaction with TCR its co-receptor. Trends Immunol. 2015;36(5):300-306.
52. Rihn SJ, et al. Extreme genetic fragility of the HIV-1 capsid. PLoS Pathog. 2013;9(6):e1003461.
53. + T cell epitope recognition paradigms. Science. 2013;340(6135):1237874.
54. Ghorashian S, et al. CD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptor. J Immunol. 2015;194(3):1080-1089.